spacer
home > pmps > spring 2007 > safe and sound
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Safe and Sound

The growing need for safety devices that meet both medical and pharmaceutical requirements results in innovative developments in prefilled syringes, argues Patrice Lewko at Rexam Pharma

Prefilled syringes have undergone dramatic development in the last 20 years, bringing more convenience and added safety. However, with the rising concern about blood borne contamination by needlesticks, the market now needs better protection for the device users. This has triggered the development of new safety systems.

Since the introduction of prefilled syringes in Europe in the 1980s, the market has enjoyed continuous growth. This trend has also been reinforced in the 1990s by the move towards injections at home by the patient.

Today, the market continues to grow by 10-20 per cent per year, depending on the geographical area, resulting in over two billion prefilled syringes sold worldwide. Their use, which was limited to heparin (Sanofi and Rhône-Poulenc) and a few other vaccines, has expanded to a whole range of new applications, such as oncology, insulin, human growth hormone, treatments for multiple sclerosis, fertility, osteoporosis, hepatitis, rheumatoid arthritis, cancer, anemia and hemophilia.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Patrice Lewko is Marketing Director for Rexam Pharma. He graduated from the Edhec Business School, France, after which he gained experience in purchasing and plastic packaging sales with Alcan (formerly Pechiney). He has been with Rexam since 1994, working in packaging solutions in both the US and Europe. Patrice is in charge of identifying the needs of the pharmaceutical industry, defining requirements and promoting the development of the corresponding products.
spacer
Patrice Lewko
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TrialScope Taps Industry Veteran as CTO

JERSEY CITY, NJ, July 29, 2019 TrialScope, the global leader in clinical trial transparency and compliance solutions, announces the appointment of Ruben Echandy as Chief Technology Officer.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals gaining strong, new industry contacts and building on existing ones.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement